Adaptive Biotechnologies Corp (ADPT): who owns it and who trades it
As of Nov 16, 2026, ADPT insiders reported 184 open-market sales worth $127M and no purchases in the last 12 months, with 77% of the sale value made under pre-set 10b5-1 plans. The largest seller was Chad M Robins (CEO), with $34.1M. 8 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Adaptive Biotechnologies
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, ADPT insiders reported $0 of open-market purchases and $127M of sales. 77% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Julie Rubinstein | President | Sale plan | 11,466 | $28.93 | $332K | Form 4 |
| Nov 12, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $29.40 | $349K | Form 4 |
| Nov 11, 2026 | Julie Rubinstein | President | Sale plan | 4,983 | $30.29 | $151K | Form 4 |
| Nov 11, 2026 | Julie Rubinstein | President | Sale plan | 6,898 | $31.22 | $215K | Form 4 |
| Nov 11, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 1,875 | $32.00 | $60K | Form 4 |
| Nov 10, 2026 | Julie Rubinstein | President | Sale plan | 9,981 | $29.35 | $293K | Form 4 |
| Nov 10, 2026 | Julie Rubinstein | President | Sale plan | 1,900 | $30.41 | $57.8K | Form 4 |
| Nov 9, 2026 | Julie Rubinstein | President | Sale plan | 1,100 | $28.87 | $31.8K | Form 4 |
| Nov 9, 2026 | Julie Rubinstein | President | Sale plan | 8,381 | $30.15 | $253K | Form 4 |
| Nov 9, 2026 | Julie Rubinstein | President | Sale plan | 2,400 | $30.58 | $73.4K | Form 4 |
| Nov 6, 2026 | Julie Rubinstein | President | Sale plan | 8,400 | $27.32 | $229K | Form 4 |
| Nov 6, 2026 | Julie Rubinstein | President | Sale plan | 3,481 | $27.88 | $97.1K | Form 4 |
| Nov 5, 2026 | Julie Rubinstein | President | Sale plan | 5,926 | $26.10 | $155K | Form 4 |
| Nov 5, 2026 | Julie Rubinstein | President | Sale plan | 5,455 | $26.88 | $147K | Form 4 |
| Nov 5, 2026 | Julie Rubinstein | President | Sale plan | 500 | $27.70 | $13.8K | Form 4 |
| Nov 4, 2026 | Julie Rubinstein | President | Sale plan | 4,000 | $25.78 | $103K | Form 4 |
| Nov 4, 2026 | Julie Rubinstein | President | Sale plan | 7,881 | $26.60 | $210K | Form 4 |
| Nov 3, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $25.98 | $309K | Form 4 |
| Nov 2, 2026 | Julie Rubinstein | President | Sale plan | 9,296 | $25.23 | $235K | Form 4 |
| Nov 2, 2026 | Julie Rubinstein | President | Sale plan | 2,585 | $26.34 | $68.1K | Form 4 |
| Oct 30, 2026 | Julie Rubinstein | President | Sale plan | 9,486 | $26.55 | $252K | Form 4 |
| Oct 30, 2026 | Julie Rubinstein | President | Sale plan | 2,395 | $27.45 | $65.7K | Form 4 |
| Oct 29, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $28.27 | $336K | Form 4 |
| Oct 28, 2026 | Julie Rubinstein | President | Sale plan | 11,681 | $28.44 | $332K | Form 4 |
| Oct 28, 2026 | Julie Rubinstein | President | Sale plan | 200 | $28.90 | $5.8K | Form 4 |
| Oct 27, 2026 | Julie Rubinstein | President | Sale plan | 3,000 | $26.58 | $79.7K | Form 4 |
| Oct 27, 2026 | Julie Rubinstein | President | Sale plan | 8,881 | $27.53 | $244K | Form 4 |
| Oct 26, 2026 | Julie Rubinstein | President | Sale plan | 8,503 | $25.94 | $221K | Form 4 |
| Oct 26, 2026 | Julie Rubinstein | President | Sale plan | 3,378 | $26.30 | $88.8K | Form 4 |
| Oct 23, 2026 | Julie Rubinstein | President | Sale plan | 4,500 | $24.50 | $110K | Form 4 |
| Oct 23, 2026 | Julie Rubinstein | President | Sale plan | 7,381 | $25.28 | $187K | Form 4 |
| Oct 22, 2026 | Julie Rubinstein | President | Sale plan | 10,181 | $24.38 | $248K | Form 4 |
| Oct 22, 2026 | Julie Rubinstein | President | Sale plan | 1,700 | $25.29 | $43K | Form 4 |
| Oct 21, 2026 | Julie Rubinstein | President | Sale plan | 5,999 | $25.25 | $151K | Form 4 |
| Oct 21, 2026 | Julie Rubinstein | President | Sale plan | 5,882 | $25.57 | $150K | Form 4 |
| Oct 20, 2026 | Julie Rubinstein | President | Sale plan | 11,781 | $24.53 | $289K | Form 4 |
| Oct 20, 2026 | Julie Rubinstein | President | Sale plan | 100 | $24.85 | $2.5K | Form 4 |
| Oct 19, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $24.05 | $286K | Form 4 |
| Oct 16, 2026 | Julie Rubinstein | President | Sale plan | 11,581 | $24.21 | $280K | Form 4 |
| Oct 16, 2026 | Julie Rubinstein | President | Sale plan | 300 | $25.45 | $7.6K | Form 4 |
| Oct 15, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $25.61 | $304K | Form 4 |
| Oct 14, 2026 | Julie Rubinstein | President | Sale plan | 6,781 | $25.57 | $173K | Form 4 |
| Oct 14, 2026 | Julie Rubinstein | President | Sale plan | 5,100 | $25.82 | $132K | Form 4 |
| Oct 13, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $25.50 | $303K | Form 4 |
| Oct 12, 2026 | Julie Rubinstein | President | Sale plan | 9,181 | $25.35 | $233K | Form 4 |
| Oct 12, 2026 | Julie Rubinstein | President | Sale plan | 2,700 | $26.07 | $70.4K | Form 4 |
| Oct 9, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $26.41 | $314K | Form 4 |
| Oct 8, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $25.66 | $305K | Form 4 |
| Oct 7, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $26.40 | $314K | Form 4 |
| Oct 6, 2026 | Julie Rubinstein | President | Sale plan | 9,381 | $27.36 | $257K | Form 4 |
| Oct 6, 2026 | Julie Rubinstein | President | Sale plan | 1,100 | $28.21 | $31K | Form 4 |
| Oct 6, 2026 | Julie Rubinstein | President | Sale plan | 901 | $29.71 | $26.8K | Form 4 |
| Oct 6, 2026 | Julie Rubinstein | President | Sale plan | 499 | $30.53 | $15.2K | Form 4 |
| Oct 6, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 6,444 | $30.00 | $193K | Form 4 |
| Oct 5, 2026 | Julie Rubinstein | President | Sale plan | 6,699 | $28.82 | $193K | Form 4 |
| Oct 5, 2026 | Julie Rubinstein | President | Sale plan | 5,182 | $29.67 | $154K | Form 4 |
| Oct 2, 2026 | Julie Rubinstein | President | Sale plan | 11,881 | $28.13 | $334K | Form 4 |
| Oct 1, 2026 | Francis Lo | Chief People Officer | Sale plan | 8,094 | $27.52 | $223K | Form 4 |
| Oct 1, 2026 | Francis Lo | Chief People Officer | Sale plan | 18,698 | $28.61 | $535K | Form 4 |
| Oct 1, 2026 | Julie Rubinstein | President | Sale plan | 6,081 | $27.57 | $168K | Form 4 |
| Oct 1, 2026 | Julie Rubinstein | President | Sale plan | 5,800 | $28.56 | $166K | Form 4 |
| Sep 16, 2026 | Francis Lo | Chief People Officer | Sale plan | 107,537 | $28.02 | $3M | Form 4 |
| Sep 16, 2026 | Francis Lo | Chief People Officer | Sale plan | 7,869 | $28.57 | $225K | Form 4 |
| Sep 15, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 1,195 | $27.00 | $32.3K | Form 4 |
| Aug 26, 2026 | Katey Einterz Owen | Director | Sale | 9,615 | $26.00 | $250K | Form 4 |
| Aug 18, 2026 | Robert Hershberg | Director | Sale | 15,000 | $24.39 | $366K | Form 4 |
| Aug 18, 2026 | Robert Hershberg | Director | Sale | 15,664 | $24.41 | $382K | Form 4 |
| Aug 18, 2026 | Chad M Robins | CEO | Sale | 204 | $25.14 | $5.1K | Form 4 |
| Aug 18, 2026 | Chad M Robins | CEO | Sale | 278,472 | $24.48 | $6.8M | Form 4 |
| Aug 17, 2026 | Chad M Robins | CEO | Sale | 2,525 | $25.57 | $64.6K | Form 4 |
| Aug 17, 2026 | Chad M Robins | CEO | Sale | 318,799 | $25.08 | $8M | Form 4 |
| Aug 17, 2026 | Peter M Neupert | Director | Sale | 69,690 | $25.16 | $1.8M | Form 4 |
| Aug 17, 2026 | Peter M Neupert | Director | Sale | 40,000 | $25.10 | $1M | Form 4 |
| Aug 17, 2026 | Peter M Neupert | Director | Sale | 15,000 | $25.23 | $378K | Form 4 |
| Aug 10, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 3,000 | $25.00 | $75K | Form 4 |
| Jul 30, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 1,299 | $24.00 | $31.2K | Form 4 |
| Jul 21, 2026 | Harlan S Robins | Chief Scientific Officer | Sale plan | 213,702 | $22.12 | $4.7M | Form 4 |
| Jul 21, 2026 | Harlan S Robins | Chief Scientific Officer | Sale plan | 278,698 | $21.72 | $6.1M | Form 4 |
| Jul 16, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 5,000 | $23.00 | $115K | Form 4 |
| Jul 15, 2026 | Francis Lo | Chief People Officer | Sale plan | 105,762 | $22.59 | $2.4M | Form 4 |
| Jul 2, 2026 | Harlan S Robins | Chief Scientific Officer | Sale plan | 239,351 | $21.74 | $5.2M | Form 4 |
| Jul 2, 2026 | Harlan S Robins | Chief Scientific Officer | Sale plan | 146,889 | $22.45 | $3.3M | Form 4 |
| Jul 2, 2026 | Francis Lo | Chief People Officer | Sale plan | 44,838 | $22.59 | $1M | Form 4 |
| Jul 1, 2026 | Francis Lo | Chief People Officer | Sale plan | 8,743 | $22.18 | $194K | Form 4 |
| Jul 1, 2026 | Francis Lo | Chief People Officer | Sale plan | 42,261 | $22.50 | $951K | Form 4 |
| Jul 1, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 487 | $22.00 | $10.7K | Form 4 |
| Jun 29, 2026 | Sharon Benzeno | Chief Commercial Ofc Imm | Sale plan | 154,768 | $21.14 | $3.3M | Form 4 |
| Jun 26, 2026 | Sharon Benzeno | Chief Commercial Ofc Imm | Sale plan | 11,034 | $21.00 | $232K | Form 4 |
| Jun 25, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 5,000 | $20.50 | $102K | Form 4 |
| Jun 25, 2026 | Michelle Renee Griffin | Director | Sale plan | 52,084 | $20.18 | $1.1M | Form 4 |
| Jun 16, 2026 | Harlan S Robins | Chief Scientific Officer | Sale plan | 6,160 | $18.01 | $111K | Form 4 |
| Jun 15, 2026 | Harlan S Robins | Chief Scientific Officer | Sale plan | 100,000 | $17.37 | $1.7M | Form 4 |
| Jun 11, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 5,000 | $19.00 | $95K | Form 4 |
| Jun 4, 2026 | Francis Lo | Chief People Officer | Sale plan | 39,741 | $17.49 | $695K | Form 4 |
| Jun 4, 2026 | Susan Bobulsky | Chief Commercial Officer | Sale plan | 11,000 | $18.00 | $198K | Form 4 |
| May 18, 2026 | Kyle Piskel | CFO | Sale | 3,115 | $13.04 | $40.6K | Form 4 |
| Apr 27, 2026 | Julie Rubinstein | President | Sale plan | 19,037 | $14.23 | $271K | Form 4 |
| Apr 24, 2026 | Julie Rubinstein | President | Sale plan | 19,060 | $14.02 | $267K | Form 4 |
| Apr 23, 2026 | Julie Rubinstein | President | Sale plan | 19,060 | $13.74 | $262K | Form 4 |
| Apr 22, 2026 | Julie Rubinstein | President | Sale plan | 19,060 | $14.13 | $269K | Form 4 |
Latest 100 of 184 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Chad M Robins | CEO and Chairman, Director | – | $34.1M | Aug 18, 2026 |
| Harlan S Robins | Chief Scientific Officer | – | $29.5M | Jul 21, 2026 |
| Julie Rubinstein | President and COO | – | $23.6M | Nov 13, 2026 |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | – | $14.7M | Jun 29, 2026 |
| Francis Lo | Chief People Officer | – | $13.9M | Oct 1, 2026 |
| Kyle Piskel | Chief Financial Officer | – | $3.6M | May 18, 2026 |
| Peter M Neupert | Director | – | $3.1M | Aug 17, 2026 |
| Michelle Renee Griffin | Director | – | $2M | Jun 25, 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | – | $1.5M | Nov 11, 2026 |
| Robert Hershberg | Director | – | $1.1M | Aug 18, 2026 |
| Katey Einterz Owen | Director | – | $250K | Aug 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ADPT short interest
Moderate short interest. 7.1% of ADPT shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 29%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.48M ADPT shares were sold short, 7.1% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 1.89M shares, buying them all back would take about 6.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.48M | 7.09% | -4% | 1.89M | 6.1 |
| Oct 15, 2026 | 11.99M | 7.51% | +1% | 2.38M | 5.0 |
| Sep 30, 2026 | 11.84M | 7.42% | -12% | 2.67M | 4.4 |
| Sep 15, 2026 | 13.49M | 8.45% | +15% | 1.71M | 7.9 |
| Aug 31, 2026 | 11.71M | 7.34% | -12% | 1.84M | 6.4 |
| Aug 14, 2026 | 13.32M | 8.35% | +7% | 2.33M | 5.7 |
| Jul 31, 2026 | 12.49M | 7.83% | +10% | 2.84M | 4.4 |
| Jul 15, 2026 | 11.40M | 7.12% | +0% | 2.65M | 4.3 |
| Jun 30, 2026 | 11.35M | 7.09% | +48% | 5.09M | 2.2 |
| Jun 15, 2026 | 7.65M | 4.78% | -7% | 2.71M | 2.8 |
| May 29, 2026 | 8.24M | 5.15% | -7% | 1.61M | 5.1 |
| May 15, 2026 | 8.90M | 5.56% | +5% | 1.96M | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Adaptive Biotechnologies company events
Adaptive Biotechnologies filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Jul 29, 2026LeadershipThe Company’s Chief Scientific Officer and Co-founder, Dr. Harlan Robins, decided to transition into a strategic consultant role with the Company. Filing
- Jun 22, 2026AgreementAdaptive Biotechnologies Corporation issued $345 million in of 0% Convertible Senior Notes due 2031. Filing
- Jun 15, 2026AnnouncementAdaptive Biotechnologies Corporation issued a press release announcing that it intends to offer, subject to market conditions and other factors, $250 million in of convertible senior notes due 2031 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the… Filing
- Jun 9, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 5, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 30, 2025AnnouncementAdaptive Biotechnologies Corporation announced that Digital Biotechnologies, Inc., a 70% owned subsidiary of the Company, held an initial closing of its Series A Preferred Stock financing, with total anticipated proceeds in the financing round of up to $15 million. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Adaptive Biotechnologies financials
Famous investors that hold ADPT
8 of the 50 well-known investors we track reported holding ADPT in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $867M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 29.99M | $867M | 2.7% | No change |
| Cathie Wood · ARK Investment Management | Q3 2026 | 1.92M | $55.5M | 0.3% | -8% |
| Israel Englander · Millennium Management | Q3 2026 | 1.22M | $35.1M | 0.0% | +141% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 867,100 | $25.1M | 0.0% | +186% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 630,283 | $18.2M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 233,354 | $6.7M | 0.0% | +29% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 71,735 | $2.1M | 0.0% | +79% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 53,601 | $1.5M | 0.0% | -90% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Adaptive Biotechnologies Corp (ADPT) stock
Are ADPT insiders buying or selling?
In the last 12 months, ADPT insiders reported no open-market purchases and 184 sales worth $127M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in ADPT?
As of Oct 30, 2026, 11.48M ADPT shares were sold short, 7.1% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 1.89M shares, buying them all back would take about 6.1 trading days (days to cover). See the history.
Which famous investors hold ADPT?
8 of the 50 well-known investors we track reported ADPT in their latest 13F filing, including Andreas Halvorsen, Cathie Wood, Israel Englander. The largest position is worth $867M. See all holders.
Executive pay
Adaptive Biotechnologies's chief executive was paid a total of $9.1M for the year ended Dec 31, 2025, up 83% from $5M the year before. In the last 12 months, Adaptive Biotechnologies's executives and directors bought no stock on the open market and sold $127M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.